Shanghai Shenqi Pharmaceutical Investment Management Co Ltd B (900904) — Working Capital to Net Assets Ratio
Shanghai Shenqi Pharmaceutical Investment Management Co Ltd B (900904) has a Working Capital to Net Assets ratio of 42.8% as of June 2025. Working capital of $1.02 Billion (current assets of $1.50 Billion minus current liabilities of $475.62 Million) is measured against net assets of $2.39 Billion. A higher ratio indicates strong short-term liquidity financed by the equity base. See 900904 financial flexibility score to measure the company's free cash flow as a share of total liabilities.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Shanghai Shenqi Pharmaceutical Investment Management Co Ltd B Working Capital to Net Assets (2015–2024)
This chart shows how Shanghai Shenqi Pharmaceutical Investment Management Co Ltd B's Working Capital to Net Assets ratio has evolved across 10 annual periods from 2015 to 2024. As of June 2025, the ratio stands at 42.8%, reflecting working capital of $1.02 Billion against net assets of $2.39 Billion USD. See Shanghai Shenqi Pharmaceutical Investmen defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.
Annual Working Capital to Net Assets for Shanghai Shenqi Pharmaceutical Investment Management Co Ltd B (2015–2024)
The table below presents the year-by-year Working Capital to Net Assets ratio for Shanghai Shenqi Pharmaceutical Investment Management Co Ltd B from 2015 to 2024, covering 10 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For live market cap and the full company profile, see how much is Shanghai Shenqi Pharmaceutical Investmen worth.
| Year | WC/NA Ratio | Working Capital (USD) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2024 | 43.9% | $1.07 Billion | $2.43 Billion | $1.60 Billion | $530.88 Million | ▼ -1.6 pp |
| 2023 | 45.4% | $1.09 Billion | $2.39 Billion | $1.77 Billion | $686.04 Million | ▲ +3.5 pp |
| 2022 | 42.0% | $995.55 Million | $2.37 Billion | $1.77 Billion | $774.34 Million | ▲ +1.6 pp |
| 2021 | 40.4% | $966.05 Million | $2.39 Billion | $1.45 Billion | $479.81 Million | ▼ -1.5 pp |
| 2020 | 41.8% | $973.89 Million | $2.33 Billion | $1.43 Billion | $457.39 Million | ▼ -6.8 pp |
| 2019 | 48.7% | $1.30 Billion | $2.66 Billion | $1.88 Billion | $583.45 Million | ▲ +0.5 pp |
| 2018 | 48.2% | $1.25 Billion | $2.60 Billion | $1.74 Billion | $487.17 Million | ▼ -2.4 pp |
| 2017 | 50.6% | $1.28 Billion | $2.53 Billion | $1.83 Billion | $546.16 Million | ▼ -4.3 pp |
| 2016 | 54.9% | $1.34 Billion | $2.43 Billion | $1.88 Billion | $546.34 Million | ▲ +0.9 pp |
| 2015 | 54.0% | $1.24 Billion | $2.29 Billion | $1.59 Billion | $357.66 Million | — |